Chemical formula: C₂₂H₃₂O₂ Molecular mass: 328.488 g/mol PubChem compound: 445580
Docosahexaenoic acid interacts in the following cases:
Due to the moderate increase in flow time (at high dosage) by omega-3 fatty acid, patients treated with anticoagulants should be monitored and, if necessary, the dosage of the anticoagulant should be adjusted.
Omega-3 fatty acids have been co-administered with warfarin without bleeding complications. However, the prothrombin time should be checked when omega-3 fatty acid are co-administered with warfarin or when treatment with omega-3 fatty acid is discontinued.
There are no adequate data from the use of docosahexaenoic acid in pregnant women.
Studies in animals have not shown reproductive toxicity. The potential risk for humans is unknown and therefore docosahexaenoic acid should not be used during pregnancy unless clearly necessary.
There are no data on the excretion of docosahexaenoic acid in animal and human milk. Docosahexaenoic acid should not be used during lactation.
There are no adequate data on the effect of docosahexaenoic acid on fertility.
Effects on ability to drive and use machines have not been studied. Nevertheless, docosahexaenoic acid is expected to have no or negligible influence on the ability to drive and use machines.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
